Harvard Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary

• Harvard Bioscience Inc HBIO.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of two analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents tozero cents per share.

• Revenue fell 11.5% to $20.45 million from a year ago; analysts expected $20.40 million.

• Harvard Bioscience Inc's reported EPS for the quarter was a loss of 5 cents​.

• The company reported a quarterly loss of $2.28 million.

• Harvard Bioscience Inc shares had risen by 18.9% this quarter and lost 75.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 100% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Harvard Bioscience Inc is $3.00, about 82.4% above its last closing price of $0.53

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)